

# Capital Allocation – Should we open Pandora's Jar?

Andrew McGuinness, Willis Towers Watson Martin Muir, Aviva



### Another allocation talk? Why now?

#### European market - shift in focus post Solvency II

- Market practice has generally converged
- BAU: stop "building" and start "using"

#### **Changing market conditions**

- Challenging conditions
- Focus on Value
- Analytics increasingly important internally and externally
- Changing economy:
  - InsureTech
  - Disaggregation
  - Disintermediation

#### **Technology continues to advance**

Take a sledgehammer to the toughest of nuts

#### **Theory vs Practice**

- Explosion of theory a decade ago
- Applications in practice have moved on little
- Time to open up the debate again!



#### Back to the fundamentals

#### **Risk Owners (indemnity seekers)**

Choose to Accept, Mitigate or Transfer

#### When we set Capital we look at:

- Risk profile
- Risk measure
- Risk tolerance
- · For a given time horizon

#### What is Capital?

- · General risk-absorbing capacity, or
- · A collection of physical instruments on a balance sheet

#### **Deployment**

- · The value of risk is not symmetric (cost of capital is undertaking-specific)
- In practice, the capital base of an undertaking is not easy to change in the short term, so it provides a constraint

#### What do we want from an allocation?

- Relationship to risk measure and risk appetite
- Appropriate consistency over time for the same risk
- Ability to deal with the time horizon for different risks
- "Coherence", which has been formally described through:
  - Full allocation
  - No undercut
  - Symmetry
  - Riskless allocation
- · No gremlins lurking in the mathematics
- Ability to implement with current models



### **Methods aplenty**

- Some of these have flavours
- Some are general principles that yield others as specific cases
- Some of them are just different names for the same thing
- They have all been talked-up and dresseddown
- And there are many more!



The **multitude of allocation methods** proposed in the literature is **bewildering**. Allocation methods are sometimes proposed in an **ad-hoc** fashion lacking usually with much economic justification and are thereby viewed as arbitrary. This motivated some authors to **doubt the legitimate purpose of the exercise itself** of allocating capital ... Certain allocation methods may be best suited in order to address specific issues, but it is always unclear what these issues are...certain allocation techniques **can dangerously lead to wrong financial decisions**."

- From 'Optimal Capital Allocation Principles', Dahene et Al, 2009



### Reviewing the literature

#### **Overview**

There are 4 main streams in the literature:

- Co-operative game theory
- Performance/portfolio management
- Market valuation of assets & liabilities
- Optimisation

#### **Practical Takeaways**

"Flurry of activity" a decade ago, picking up again recently

Papers often aimed at addressing the shortfalls of methods so far

Realistic examples are relatively scarce

Slow groundwork – academics tend to worry about housekeeping

Bibliography and my potted summary notes can be found with the slides on the GIRO website

#### **Recent Highlights**

- Furman et Al (2018)
  - Analyse the Weighted Insurance Pricing Model under multiplicative and additive systematic-risk frameworks
  - Quite "useful" distributions allowed for
  - Dependency through explicit effects analogous to CAPM
- Boonen et Al (2017)
  - Capital allocation with non-linear risk aggregation
- Major (2018)
  - Allocation for financial derivatives of some underlying e.g. reinsurance recoveries
  - Relies on homogeneity of the operator
- Tsanakas et Al 2018 (preprint)
  - Response to Major (2018)
  - Allocation of net rather than gross total



### Theory vs. practice

By the "no free lunch theorem", there is never going to be one best method for all circumstances

Capital allocation is not an end in itself – the reason behind allocation should drive the choice of methods

### What business problems are people using capital allocations for?

- Filling in regulatory returns
- Understanding the behaviour of the internal model / validation
- Business planning / strategy
- Pricing
- · Performance management

#### **Challenges:**

- Nitty-gritty e.g. separating insurance and market risk on discounted profits
- The time horizon
- Expert judgement and its impact

#### Market practice: which methods are popular?

The following relatively non-exotic methods seem to be dominant:

- Haircut (or pro-rata)
- Co-TVaR
- Kernel (or Fuzzy VaR or Spread-VaR)

Most current models use Monte Carlo simulation – so any method needs to be amenable to simulation output

Often we hope to fit an allocation method onto an arbitrary model – maybe that's asking too much

It can be difficult to frame many business questions in a "model world"

A common question I get asked is whether market practice has moved on to something more exciting, to which my common answer is "no, but maybe it should!"



### Where do we go from here?

- Call to arms don't give up!
- Some methods have nicer theoretical properties than others
  - Just changing your allocation method won't help you
  - But why not experiment a little?
- I think there is an opportunity for research on the whole process (not just the allocation methods)
- We will need to change our models as the world moves on
  - Usefulness for allocation should be a design consideration





### What do we mean by capital allocation?

#### **Deploying to and releasing capital from:**

Products

Debtholders

Debtholders

Shareholders

Pension scheme members

#### **Objectives:**

- Support the strategy
- Drive better financial outcomes.

"The root of my success is acting rationally about capital allocation."

Warren Buffet, CEO Berkshire Hathaway



### Where is capital allocation used?





### What measures are needed to allocate capital?

#### Do we need another measure?

- · We already have many! Want greater simplicity not additional complexity
- Finance and Risk may enjoy using it, but how will the Business understand and use it?

	Growth Oriented	Wide Application	Risk & Return
Operating Profit			
Operating Capital Generation			
Value of New Business			
Net Written Premiums			
Combined Operating Ratio			
Cash Remittance			



### Practical considerations just as important





### **Capital allocation metrics**


What's the right type of metric?





### **Technical choices (1)**


What's the right value measure?





### **Technical choices (2)**

What's the right capital measure?







### How we use it - examples (1)

Metric	Cash payback (years)	EVA +ve @ WACC of swaps plus
No escalation required	Less than X years	>%
Local CFO escalation	X-X years	%-%
Group escalation	More than X years	<%

#### Lifetime EVA vs initial capital strain (gain)




#### **GI product EVA**





### How we use it - examples (2)

#### M&A



Solvency 2 "Day 1" impact

IPurchase price
Own funds acquired
"Initial" EVA
ISCR at acquisition
Diversification benefit
"Day 1" Group S2 impact


PV EVA - 8%
IPV EVA - 9%
IPV EVA - 10%

■ Own funds movement ■ EVA



### How we use it - examples (3)

#### **BU** performance





### **Embedding it**

Be pragmatic



- Use readily available numbers
- No new complex concepts
- Proportionate approach

Stakeholder Engagement



- Early consultation, let people help shape it
- Demonstrate the business value
- Compromise! Don't ignore concerns

**Education** 



- Internal training
- Be able to pitch at different levels
- Repeat and persevere!




### Market focusing on sustainable growth

Gaining traction with analysts, gradual shift from an IFRS to an S2 lens

Solvency II valuation – Price to shareholder Own Funds vs operating return on FY17 Own Funds (%)

The ability for insurers to demonstrate underlying growth in Own Funds could increase in prominence for investors



Operating return on Own Funds is an under-appreciated metric in our view



Source: UBS research, company data, Solvency and Financial Condition Reports (SFCRs), Datastream, all local currency, FY17 Own Funds

## Questions

### Comments

The views expressed in this [publication/presentation] are those of invited contributors and not necessarily those of the IFoA. The IFoA do not endorse any of the views stated, nor any claims or representations made in this [publication/presentation] and accept no responsibility or liability to any person for loss or damage suffered as a consequence of their placing reliance upon any view, claim or representation made in this [publication/presentation].

The information and expressions of opinion contained in this publication are not intended to be a comprehensive study, nor to provide actuarial advice or advice of any nature and should not be treated as a substitute for specific advice concerning individual situations. On no account may any part of this [publication/presentation] be reproduced without the written permission of the IFoA [or authors, in the case of non-IFoA research].

